Details

---

Manufacturer
Pfizer Manufacturing Deutschland GmbH.(GERMANY)

Registraction Number
MAL24066001AZ

Content:

• Active Ingredient: Abrocitinib 50 mg
• Excipients/Inactive Ingredients: Microcrystalline cellulose, Anhydrous dibasic calcium phosphate, Sodium starch glycolate, Magnesium stearate, Hypromellose (E464), Titanium dioxide (E171), Lactose monohydrate, Macrogol, Triacetin (E1518), Iron red oxide (E172).

Indications:
Cibinqo is indicated for the treatment of adults and pediatric patients aged 12 years and older with refractory, moderate-to-severe atopic dermatitis (eczema) whose disease is not adequately controlled with other systemic drug products, including biologics, or when the use of those therapies is inadvisable.
Instructions:

1. Dosage:
   • The recommended starting dose is 100 mg or 200 mg once daily, based on individual patient characteristics.
   • Upon disease control, the dose should be decreased to 100 mg once daily.
   • If disease control is not maintained after dose reduction, re-treatment with 200 mg once daily can be considered.
2. Administration:
   • Take Cibinqo once a day, at the same time each day.
   • Swallow the tablet whole with water and do not crush, chew, or break it.
   • You may take Cibinqo with or without food.
3. Monitoring:
   • Regular monitoring by a dermatologist or physician specializing in atopic dermatitis is recommended.
   • Watch for signs of adverse effects, such as venous thromboembolism (VTE), major adverse cardiovascular events (MACE), and malignancy.